Boehringer Ingelheim to support the ADA’s proven Community Hub model
The American Diabetes Association® (ADA) is committed to improving access to health care, education, and resources that impact health for people living with or at risk for diabetes and cardio-renal-metabolic (CRM) complications.
Today, the ADA is excited to announce a two-year collaboration with Boehringer Ingelheim that supports this work and will address health barriers to accessing care and disease prevention education for people impacted by diabetes and CRM complications.
This collaboration will focus on improving access to care with early interventions and risk-reduction strategies. For the first phase of implementation, the ADA will partner with organizations in Birmingham and Montgomery, Alabama. Using its proven Community Hub model, the ADA will engage with local community organizations linked together to act as a physical hub to establish an ecosystem to educate people about the risks of diabetes and chronic kidney disease (CKD).
“Diabetes is the leading cause of kidney disease, so it is crucial that we educate people about CKD and their risk for developing diabetes as well as CKD,” said Charles “Chuck” Henderson, the ADA’s chief executive officer. “We know that not everyone has access to the education and care they need to thrive. By going into local communities, we are able to meet people where they are alongside the professionals and organizations that they trust to drive true change and improve health outcomes in that community.”
By starting this collaboration in two communities, the ADA will develop scalable and sustainable solutions that can be replicated in other communities.
“By teaming up with the ADA, we aim to create lasting community-based solutions for improving primary prevention, early screening, diagnosis, and care,” said Celeste Woolfork, director of MORE HEALTH at Boehringer Ingelheim. “This collaboration underscores both Boehringer’s and ADA’s commitment to patients and our continued dedication to disease prevention education.”
###
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure diabetes—and we’re not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we’re fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn).
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more: www.boehringer-ingelheim.com/us.
